Sorafenib, a multi-kinase inhibitor, blocks multiple pathways involved in the development and progression of AML, such as FLT3-ITD, Ras/Raf, c-KIT as well as vascular endothelial growth factor and platelet-derived growth factor receptors (PDGFR) [3]. Here, FLT3 is linked to acute myeloid leukemia.